OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser's Option to Purchase Additional NotesGlobeNewsWire • 01/09/24
OPKO Health Announces Pricing of Private Offering of $200 Million Convertible Senior Notes Due 2029GlobeNewsWire • 01/05/24
BioReference Health and Prognos Health Collaborate to Advance Precision Medicine and TestingPRNewsWire • 11/28/23
BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™PRNewsWire • 11/07/23
OPKO Health (OPK) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 11/07/23
OPKO Health Reports Third Quarter 2023 Business Highlights and Financial ResultsGlobeNewsWire • 11/06/23
New Clinical Data on OPKO Health's RAYALDEE® (ER Calcifediol) Presented at Kidney Week 2023GlobeNewsWire • 11/02/23
OPKO Health to Report Third Quarter 2023 Financial Results on November 6, 2023GlobeNewsWire • 10/31/23
OPKO Health to Present New Clinical Data on Rayaldee (ER Calcifediol) at Kidney Week 2023GlobeNewsWire • 10/25/23
ModeX Therapeutics Secures BARDA Contract to Develop Novel Multispecific Antibodies Against Viral Infectious Disease ThreatsGlobeNewsWire • 09/28/23
OPKO Health: Improving Profitability Should Drive Shares Forward Post Q2 EarningsSeeking Alpha • 07/31/23
OPKO Health to Report Second Quarter 2023 Financial Results on August 3, 2023GlobeNewsWire • 07/25/23